title: Changes in cortical thickness in the frontal lobes in schizophrenia are a result of thinning of pyramidal cell layers.
abstract: Decreased cortical thickness and reduced activity as measured by fMRI in the grey matter of the subgenual cingulate cortex have been reported in schizophrenia and bipolar disorder, and cortical grey matter loss has been reliably reported in the frontal and temporal lobes in schizophrenia. The aim of this study was to examine the thickness of each of the six cortical layers in the subgenual cingulate cortex, five frontal lobe and four temporal lobe gyri. We examined two separate cohorts. Cohort 1 examines the subgenual cingulate cortex (SCC) in schizophrenia (n = 10), bipolar disorder (n = 15) and major depressive disorder (n = 20) against control subjects (n = 19). Cohort two examines frontal and temporal gyri in schizophrenia (n = 16), major depressive disorder (n = 6) against matched controls (n = 32). The cohorts were selected with identical clinical criteria, but underwent different tissue processing to contrast the effect of chemical treatment on tissue shrinkage. Measurements of layer I-VI thickness were taken from cresyl-violet- and haematoxylin-stained sections in cohort one and from cresyl-violet- and H&E-stained sections in cohort two. SCC cortical thickness decreased in male subjects with bipolar disorder (p = 0.048), and male schizophrenia cases showed a specific decrease in the absolute thickness of layer V (p = 0.003). Compared to controls, the relative thickness of layer V in the crown of the SCC decreased in schizophrenia (p < 0.001). A significant decrease in total cortical thickness was observed across the frontal lobe in schizophrenia (p < 0.0001), with specific pyramidal layer thinning in layers III (p = 0.0001) and V (p = 0.005). There was no effect of lateralization. No changes were noted in temporal lobe cortical thickness. This study demonstrates diminished pyramidal layer thickness resulting in decreased frontal lobe thickness in schizophrenia.
authors.affiliation: Neuropathology Unit, Department of Experimental Medicine, Imperial College London, Charing Cross Hospital, UK. Matthew.r.williams@imperial.ac.uk
authors.forename: M R
authors.initials: MR
authors.lastname: Williams
authors.forename: R
authors.initials: R
authors.lastname: Chaudhry
authors.forename: S
authors.initials: S
authors.lastname: Perera
authors.forename: R K B
authors.initials: RK
authors.lastname: Pearce
authors.forename: S R
authors.initials: SR
authors.lastname: Hirsch
authors.forename: O
authors.initials: O
authors.lastname: Ansorge
authors.forename: M
authors.initials: M
authors.lastname: Thom
authors.forename: M
authors.initials: M
authors.lastname: Maier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D048588:Benzoxazines; D001714:Bipolar Disorder / Q000473:pathology; D015331:Cohort Studies; D003865:Major Depressive Disorder / Q000473:pathology; D005260:Female; D005625:Frontal Lobe / Q000473:pathology*; D006416:Hematoxylin; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D017966:Pyramidal Cells / Q000473:pathology*; D012559:Schizophrenia / Q000473:pathology*; D012737:Sex Factors
chemical_list: D048588:Benzoxazines; C028911:cresyl violet; D006416:Hematoxylin